SHANGHAI JUNSHI BIOSCIENCES CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.66 HKD | -0.87% |
|
+8.24% | -29.73% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18,711 | 64,649 | 56,686 | 57,119 | 35,947 | 25,971 | - | - |
| Enterprise Value (EV) 1 | 18,402 | 62,115 | 53,714 | 52,363 | 33,930 | 24,000 | 25,005 | 24,016 |
| P/E ratio | -24.9 x | -23.4 x | -59.1 x | - | - | -9.61 x | -16.8 x | -13.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 24.1 x | 40.5 x | 14.1 x | 39.3 x | 23.9 x | 12.8 x | 8.27 x | 6.32 x |
| EV / Revenue | 23.7 x | 38.9 x | 13.3 x | 36 x | 22.6 x | 11.9 x | 7.96 x | 5.85 x |
| EV / EBITDA | -23.5 x | -41.7 x | -127 x | -21.7 x | -15.7 x | -19.1 x | -31.2 x | -27.3 x |
| EV / FCF | -9.3 x | -30.5 x | -38 x | -24.1 x | -12 x | -11.9 x | -15.1 x | -17.2 x |
| FCF Yield | -10.8% | -3.28% | -2.63% | -4.14% | -8.35% | -8.39% | -6.64% | -5.81% |
| Price to Book | 6.26 x | 7.14 x | 5.17 x | - | - | 1.77 x | 1.95 x | 1.85 x |
| Nbr of stocks (in thousands) | 784,147 | 872,496 | 910,757 | 982,872 | 985,011 | 984,908 | - | - |
| Reference price 2 | 23.86 | 47.81 | 47.26 | 42.83 | 17.67 | 12.75 | 12.75 | 12.75 |
| Announcement Date | 3/2/20 | 2/26/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 775.1 | 1,595 | 4,025 | 1,453 | 1,503 | 2,023 | 3,141 | 4,107 |
| EBITDA 1 | -783.5 | -1,490 | -422 | -2,417 | -2,168 | -1,257 | -800.3 | -880 |
| EBIT 1 | -747.3 | -1,636 | -558.3 | -2,666 | -2,457 | -1,552 | -860.1 | -38.37 |
| Operating Margin | -96.41% | -102.59% | -13.87% | -183.41% | -163.55% | -76.71% | -27.39% | -0.93% |
| Earnings before Tax (EBT) 1 | -763.1 | -1,672 | -595 | -2,677 | -2,492 | -1,535 | -758.9 | -64.33 |
| Net income 1 | -747.4 | -1,669 | -720.9 | -2,388 | -2,283 | -1,413 | -698.5 | -119.3 |
| Net margin | -96.43% | -104.62% | -17.91% | -164.3% | -151.97% | -69.81% | -22.24% | -2.91% |
| EPS 2 | -0.9600 | -2.040 | -0.8000 | - | - | -1.327 | -0.7589 | -0.9550 |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,833 | -2,021 | -850.5 | -399 |
| FCF margin | -255.28% | -127.71% | -35.14% | -149.31% | -188.58% | -99.89% | -27.08% | -9.71% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/26/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 309 | 2,534 | 2,972 | 4,756 | 2,017 | 1,971 | 966 | 1,956 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,833 | -2,021 | -851 | -399 |
| ROE (net income / shareholders' equity) | -23.6% | -37.7% | -10.4% | -32.7% | -27.3% | -21.9% | -10.9% | -0.31% |
| ROA (Net income/ Total Assets) | -17.1% | -26.8% | -9.24% | - | -18.8% | -14.7% | -6.78% | -0.61% |
| Assets 1 | 4,360 | 6,228 | 7,802 | - | 12,138 | 9,629 | 10,309 | 19,425 |
| Book Value Per Share 2 | 3.810 | 6.690 | 9.150 | - | - | 7.200 | 6.550 | 6.890 |
| Cash Flow per Share 2 | -0.9100 | -1.780 | -0.7200 | - | - | -1.220 | -0.5700 | - |
| Capex 1 | 792 | 580 | 772 | 394 | 828 | 630 | 452 | 373 |
| Capex / Sales | 102.13% | 36.4% | 19.19% | 27.1% | 55.14% | 31.14% | 14.38% | 9.08% |
| Announcement Date | 3/2/20 | 2/26/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.75
CNY
Average target price
22.86
CNY
Spread / Average Target
+79.27%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.73% | 3.6B | |
| -2.32% | 92.59B | |
| +3.16% | 41.43B | |
| -11.10% | 33.49B | |
| +53.42% | 25.06B | |
| -9.41% | 12.77B | |
| -12.25% | 11.58B | |
| -44.00% | 11.35B | |
| +5.92% | 8.97B | |
| -5.96% | 8.3B |
- Stock Market
- Equities
- 1877 Stock
- Financials Shanghai Junshi Biosciences Co., Ltd.
